October 19, 2026
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
October 14, 2026
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
October 13, 2026
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 30, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
September 21, 2026
Change to American Depositary Share Ratio
September 11, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
August 20, 2026
Immutep Corporate Presentation
June 4, 2026
EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic
May 31, 2026
ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients
February 20, 2026
December 2, 2025
SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
November 13, 2025
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
October 23, 2026 – October 27, 2026
ESMO Congress 2026
Madrid, Spain
November 9, 2026 – November 11, 2026
BIO-Europe
Koelnmesse, Cologne, Germany
December 1, 2026 – December 2, 2026
Clinical Trials in Oncology and Rare Diseases Europe 2026
Munich, Germany
Please fill in your details and marketing permissions below. * indicates required.
Immutep Limited will use the information you provide on this form to be in touch with you and to provide updates and marketing. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at immutep@citadelmagnus.com.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices.
